Literature DB >> 1328074

Prevention of programmed cell death in Burkitt lymphoma cell lines by bcl-2-dependent and -independent mechanisms.

A E Milner1, G D Johnson, C D Gregory.   

Abstract

Burkitt lymphoma (BL) cell lines which retain the phenotypic characteristics of the freshly-isolated tumour cells (group I cells) readily enter programmed cell death (apoptosis) in response to a variety of triggers. By contrast, isogenic BL cells which are phenotypically altered as a result of activation of their resident EBV genome (group-III cells) are highly protected from apoptosis. Phenotypic changes in group-III cells include the up-regulation of the oncogene, bcl-2. Expression of the 26-kDa bcl-2 protein in group-I BL cells following gene transfer was found to afford protection from apoptosis: the degree of protection was proportional to the amount of bcl-2 protein expressed. When group-I bcl-2 transfectants were compared with their group-III counterparts it was found that, whilst bcl-2 made a significant contribution in protecting from entry into apoptosis, hyper-expression of bcl-2 protein in group-I cells (well beyond that of group-III cells) was necessary to attain the high levels of protection observed in group-III cells. These results suggested that additional, bcl-2-independent, survival mechanisms could operate in BL cells. In support of this notion it was also found that: (1) prolonged culture of group-I lines in vitro resulted in enhanced survival in the absence of bcl-2 up-regulation, and (2) exposure of group-I cells to interferon-alpha triggered a bcl-2-independent protective response. The molecular mechanisms of both the bcl-2-dependent and -independent survival pathways remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328074     DOI: 10.1002/ijc.2910520424

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Role of bcl-2 in Epstein-Barr virus-induced malignant conversion of Burkitt's lymphoma cell line Akata.

Authors:  J Komano; K Takada
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus.

Authors:  L C Spender; E J Cannell; M Hollyoake; B Wensing; J M Gawn; M Brimmell; G Packham; P J Farrell
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Apoptosis and its control in cell culture systems.

Authors:  R P Singh; G Finka; A N Emery; M Al-Rubeai
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

4.  Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death.

Authors:  S Henderson; D Huen; M Rowe; C Dawson; G Johnson; A Rickinson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

5.  Cloned Shiga toxin 2 B subunit induces apoptosis in Ramos Burkitt's lymphoma B cells.

Authors:  Paola Marcato; George Mulvey; Glen D Armstrong
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line.

Authors:  B D'Souza; M Rowe; D Walls
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma.

Authors:  I K Ruf; P W Rhyne; H Yang; C M Borza; L M Hutt-Fletcher; J L Cleveland; J T Sample
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

8.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.

Authors:  L Guedez; W G Stetler-Stevenson; L Wolff; J Wang; P Fukushima; A Mansoor; M Stetler-Stevenson
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

9.  Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor.

Authors:  Brendan N D'Souza; Leonard C Edelstein; Pamela M Pegman; Sinéad M Smith; Sinéad T Loughran; Ann Clarke; Anja Mehl; Martin Rowe; Céline Gélinas; Dermot Walls
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis.

Authors:  J L Gala; C Vermylen; G Cornu; A Ferrant; J L Michaux; M Philippe; P Martiat
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.